Showing results (941-950 of 967) with videos related to
Sort By:
Pageof 97
The Kaohsiung Journal of Medical Sciences|October 27, 2023
Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogsTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.Alimentary Pharmacology & Therapeutics|May 21, 2025
Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B StudyRui Huang, Ai-Thien Do, Hidenori Toyoda, et al.Hepatology International|September 7, 2022
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohortYao-Chun Hsu, Dae Won Jun, Cheng-Yuan Peng, et al.Eclinicalmedicine|August 20, 2025
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyRui Huang, Dae Won Jun, Hidenori Toyoda, et al.Clinical and Molecular Hepatology|March 17, 2025
Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatmentRui Huang, Dae Won Jun, Hidenori Toyoda, et al.Journal of Viral Hepatitis|September 13, 2025
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide AnalogsAngela Chau, Jie Li, Dae Won Jun, et al.Hepatology International|January 4, 2021
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patientsMatt Liu, Tai-Chung Tseng, Dae Won Jun, et al.Journal of Cancer Research and Clinical Oncology|March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patientsMargherita Rimini, Mara Persano, Toshifumi Tada, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision MedicineJiyoon Park, An K Le, Tai-Chung Tseng, et al.Targeted Oncology|March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?Margherita Rimini, Mara Persano, Toshifumi Tada, et al.Pageof 97